Editorial


Nature Biotechnology 25, 1375 (2007)
doi:10.1038/nbt1207-1375

Beyond interferon


Interferon (IFN)-alpha has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.

Top



Extra navigation

Subscribe to Nature Biotechnology

Subscribe

naturejobs

natureproducts


ADVERTISEMENT